Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

MLX Fearless, the Largest Chiropractic Event of the Year, is Finally Here


Are you ready for MLX Fearless?! MaxLiving is hosting a chiropractic seminar with guest speakers Dr. Billy DeMoss, Dr. Nick Wilson, Dr. Erin Zovath, other chiropractic leaders, and a surprise guest for a once-in-a-lifetime weekend of empowerment and truth through principle. This seminar is for the principled chiropractor looking to restore faith and wellness amongst the community during this time of fear. These breakout sessions will revitalize the modern chiropractor and restore the principled approach to chiropractic and wellness through informative sessions, mindful practices, and networking with leaders in the chiropractic and holistic health community.

MLX Fearless was created to give chiropractors the opportunity to hear and learn from the renowned Dr. Billy DeMoss, Dr. Nick Wilson, and Dr. Erin Zovath speak about their success in spreading the message of chiropractic. Plus, MaxLiving will drive forward the conversation about the current state of health and fear today and discuss how to turn patients from fearful individuals into warriors of wellness.

MaxLiving’s mission of health is more essential now than ever before. This is an opportunity to take control in a time of chaos and isolation, spreading the message of true wellness with the help of MaxLiving’s principled approach and resources of an international network.

With the current quarantine, chiropractors across North America are unable to travel. That is why MaxLiving created the MLX Fearless Virtual to engage in the principle of chiropractic from the comfort of their own home. Master how to become the authority figure destined to restore faith back into the communities.

To register for this virtual event, go to https://go.maxliving.com/chiropractic-webinar/

If you are interested in joining the MaxLiving network or in MaxLiving wholesale product opportunities, contact Emily Pugh-Oliver, MaxLiving Doctor Sales Associate, at emily.oliver@maxliving.com.

For press information and media resources, please contact Ray Leake, MaxLiving, at (321) 939-3060, or ray.leake@maxliving.com

MaxLiving is a natural healthcare organization founded on five core principles of wellness. The 5 Essentials™ is a natural and effective way to maximize your health by integrating core chiropractic, mindset, nutrition, exercise and oxygen, and minimizing toxin exposure. Our vision of chiropractic and holistic healthcare is recognized through a group of chiropractor partners and practices. MaxLiving exists to transform lives by providing educational seminars, coaching programs, franchise opportunities, and nutritional products and services. We want to educate about the power of chiropractic care and empower people to live a healthy, balanced lifestyle.

Share article on social media or email:

Health, wellness expert founds Triple Crown of Wellness


What can we do to achieve our optimal health in the world we live in today?

The time is now to empower ourselves and ask the question, “What can we do to achieve our optimal health in the world we live in today?” The Triple Crown of Health and Wellness has the answer and consists of cutting-edge alternative health modalities that have been proven and studied for decades.

The founder of the Triple Crown, Dr. Janet Franco, a.k.a. Soulful Rosie, is a humanitarian and veterans advocate who has worked with the top doctors, scientists and researchers in the world to find the safest and most natural breakthroughs in health and wellness. Franco, who has an honorary doctorate for her work helping to save the lives of more than 6,000 veterans, works with Dr. Denise Tropea, a podiatrist, foot surgeon and wound care specialist. Tropea maintained a private practice for 25 years in Las Vegas before closing her office to pursue her passion for alternative medicine. Together, Franco and Tropea launched a website and have been conducting webinars to bring accurate information and education to the public.

The three categories of the Triple Crown are oxygen, DNA nutrition and repair, and quantum technology. The most effective way to increase oxygen delivery to the body is by increasing atmospheric oxygen and improving microcirculation. The second component, DNA nutrition and repair, is the cornerstone to strengthening and supporting the immune system. The last component is quantum technology. Franco collaborated with researched Warren Hanchey, developer of hologram technology, to help mitigate harmful electromagnetic frequencies such as 5G.

“I have been working with Dr. Janet and Dr. Denise for the last year now, and love their attitudes and goals for the Triple Crown of Health and Wellness,” Hanchey said. “They understand the biological issues with high frequency radiation and know, if not managed, it is a clear and present danger to humanity and all living things.”

To further their mission, both women appeared on the Charlie Ward show Thursday, Sept. 10. Ward’s program can be heard at http://www.drcharlieward.co.uk/. For more information on The Triple Crown of Wellness, or to view weekly broadcasts, visit triplecrownofhealthandwellness.com and click on the microphone to view shows.

Share article on social media or email:

Accuhealth Remote Patient Monitoring Service Surpasses 250,000 Patient Readings Per Month


With 260,000 readings a month, it not only shows that our platform is scalable, but also that people are using it and it’s sustainable. This also provides a good foundation to begin our predictive analytics and machine learning program

Accuhealth is pleased to announce over 250,000 patient readings per month, a major growth milestone for the healthcare technology company. Accuhealth now has collected enough data to work with leading experts in the field of machine learning to expand the company’s remote patient monitoring (RPM) capabilities. This will also allow the company to pursue its goal of integrating data-based discoveries for improved predictions of the likelihood of patients experiencing adverse medical events.

Accuhealth CEO Stephen Samson commented, “With 260,000 readings a month, it not only shows that our platform is scalable, but also that people are using it and it’s sustainable. This also provides a good foundation to begin our predictive analytics and machine learning program, which will provide even more insight for the many physicians who use our platform to treat their chronically ill patients.”

Since its inception in 2018, Accuhealth’s leadership team knew that providing an easy-to-use, functional piece of technology for physicians would be the secret to the program’s success, eliminating barriers between physicians and their patients and becoming a major contender in the RPM space. Surpassing 250,000 readings is an indication that this is now a reality, and that Accuhealth can pursue new opportunities in machine learning and artificial intelligence.

Accuhealth’s RPM platform provides a 24/7 live interactive dashboard view of thousands of patients’ biometric data and functions as a communication medium between physicians, care providers, and the patients themselves – often identifying or helping prevent potential adverse healthcare events before they worsen. Patients can monitor their medical conditions by simply logging into Accuhealth’s web-based platform. Additionally, with an integrated telemedicine module, physicians using Accuhealth’s HIPAA-compliant RPM solution are one click away from providing virtual visits easier and faster than most built-in electronic health records (EHR) solutions.

Samson added, “Critical to Accuhealth’s growth has been the ability of our RPM platform to integrate with most practice-based EHRs. Our clinics love our EHR integrations and they rely on our robust integrations to help them with making RPM easy to deploy and give them the data they need for quality reporting.”

Accuhealth provides clinics across the United States – including Hawaii and Alaska – with this turn-key RPM service, which satisfies Medicare CPT 99453, 99454, 99457, and 99458. They also work Texas Medicaid Telemonitoring Codes CPT 99423, 99422, and 99421 RPM programs. Find out more at https://www.linkedin.com/company/accuhealth

Share article on social media or email:

DNA Diagnostics Center® Launches Baby Gender Early Detection Test (Peekaboo™)


DNA Diagnostics Center® (DDC®), a global leader in genetic relationship testing, announced today the launch of Peekaboo™, an early detection test that determines fetal gender using advanced DNA testing. The highly-accurate test can inform expectant parents of their baby’s gender as early as 7 weeks into pregnancy, as opposed to the 18-22 weeks typical for traditional ultrasound gender detection.

With a clinically-proven accuracy rate of 99.5%, Peekaboo sets the standard for performance and is the only early gender reveal test endorsed by the American Pregnancy Association (APA).

“Because DNA Diagnostics Center is highly accredited and consistently delivers premium-quality testing and care, the American Pregnancy Association recommends DNA Diagnostics Center for a wide range of testing needs” said Lynn Handley, President of the APA. “We’re excited they are now offering a new gender-reveal test that will deliver accurate results sooner than anything else on the market.”

Test accuracy was validated in an extensive study that compared maternal self-collected blood samples and matched professional venous-blood draws. Cell-free fetal DNA was isolated from the samples and then tested for fetal-sex determination using both Peekaboo and next-generation sequencing for comparison.

“While next-generation sequencing is one of the most clinically exacting methodologies available, it is cost-prohibitive for parents primarily interested in an early-gender reveal” said Michael Baird, Ph.D., Chief Science Officer at DDC. “With Peekaboo, our scientists were able to design a highly-accurate test that utilizes cell-free fetal DNA without the complexities and expense of next-generation sequencing.”

Consumer demand for gender-reveal testing has grown significantly in recent years, with an increasing interest in early detection to better plan for the baby’s arrival. To support this demand, DDC has developed Peekaboo, an at-home test kit, as well as Peekaboo PRO, an in-office kit for healthcare professionals.

“During these unprecedented times, milestone events in our life carry even greater meaning and importance” said Scott Cramer, DDC President and CEO. “The Peekaboo baby gender early detection test is a natural extension of our portfolio and one that we wanted to ensure has the highest level of performance, whether DNA is collected at home or at the healthcare provider’s office. Having successfully performed over 20 million DNA tests since our inception, we are proud to introduce this exciting new test.”    

Both the at-home Peekaboo and clinical Peekaboo PRO test kits are now available for purchase at DNAcenter.com, and the at-home kit can also be purchased on Amazon.com.

About DNA Diagnostics Center (DDC):

Founded in 1995, DDC is one of the largest private DNA-testing companies, offering diagnostic and genetic tests to help answer relationship, fertility, and health and wellness questions. DDC continues to expand its presence in the testing market through both its internal R&D efforts as well as acquisitions.

DDC provides products approved by the FDA and EMA, and is accredited by the American Association of Blood Banks (AABB), The Ministry of Justice, The College of American Pathologists (CAP), and The Clinical Laboratory Improvement Amendment (CLIA). DDC is also accredited by ACLASS to meet the international standards of ISO 17025 and the American Society of Crime Laboratory Directors / Laboratory Accreditation Board-International (ASCLD/LAB).

For more information, visit dnacenter.com.

Share article on social media or email:

Signature Orthodontics Relaunches Website With Updated Hybrid-Responsive Design


Signature Orthodontics

Signature Orthodontics

We are pleased to give patients the ability to easily navigate a website with comfort and ease. Our website contains any necessary information for our current patients and is also for anyone who would like to learn more about our products and services.

Signature Orthodontics of St. Paul and White Bear Lake, MN is excited to announce the launch of their new Hybrid-Responsive™ website: https://www.signaturesmilesmn.com.

Dr. Wendy Sydlewski takes an innovative approach to orthodontics at her practice, which is why she wanted a modern website that embraces the latest in responsive design. With its advanced features, informative content, and clean aesthetic, Signature Orthodontics’ new website is a perfect match for this forward-thinking team of dental professionals.

“We are pleased to give patients the ability to easily navigate a website with comfort and ease. Our website contains any necessary information for our current patients and is also for anyone who would like to learn more about our products and services,” says Dr. Wendy Sydlewski.

Patient experience is at the forefront of the new Signature Orthodontics website. Hybrid-Responsive design embraces the latest in usability research to build websites that take into account how people interact with brands and businesses online. The updated website is equally responsive on desktop computers, laptops, tablets, and smartphones, offering a seamless online experience. Now, whether their patients are at home, at work, or on-the-go, they’ll be able to get the information they need and connect with the team at Signature Orthodontics.

The new Signature Orthodontics website is simple to navigate, with clear menu options and categories. With a few clicks or taps on the screen, patients can fill out new patient forms, make an appointment request, contact the practice with questions, or learn more about their orthodontic treatment options.

Another way Signature Orthodontics is embracing new technology is through its implementation of teledentistry services. Their virtual care appointments allow patients to check in with Dr. Sydlewski from the comfort of their own homes. The practice has rolled out a comprehensive COVID-19 safety plan and the use of teledentistry is one of the many protocols being used to keep both patients and staff safe during the pandemic.

About Dr. Wendy Sydlewski

Dr. Wendy Sydlewski, MD, DDS isn’t only an orthodontist — she’s also a medical doctor. In addition to her dental school degree, she received years of additional training to become an orthodontist, then four more years of education to become a medical doctor. This gives her unique insight into both the dental and medical implications of teeth alignment, jaw and palate position, and facial growth patterns. A recipient of the Minnesota Association of Orthodontics Achievement Award, Dr. Sydlewski is a member of the American Dental Association, the American Association of Orthodontics, and a former faculty member of the University of Minnesota orthodontic residency program.

About Signature Orthodontics

Signature Orthodontics is a premier provider of orthodontic services in St. Paul and White Bear Lake, MN. In addition to early and two-phase orthodontic treatment, Signature Orthodontics specializes in airway orthodontics, surgical orthodontics, Invisalign treatment, and AcceleDent.

To learn more or request an appointment, visit the new website at https://www.signaturesmilesmn.com or contact the practice at one of its two locations:

2126 5th Street

White Bear Lake, MN 55110

Phone: 651-426-9986

1575 7th St. West, Suite 102

St. Paul, MN 55102

Phone: 651-291-9011

Share article on social media or email:

The critical aspects to consider when choosing the right CDMO for your HPAPI Development, Manufacturing & Packaging, Upcoming Webinar Hosted by Xtalks


Xtalks Logo

Xtalks Life Science Webinars

This webinar is designed to combine theory with practice, drawing on the experience built up over 35 years of working in this specialist space.

With the complexities involved in the safe handling of potent molecules and increasing regulatory requirements, it is imperative to choose the right partner for the successful development, manufacturing, packaging and ultimate commercialization of such molecules.

Join David O’Connell BSc (Hons), Director of Scientific Affairs, PCI Pharma Services and Michael Ellingson, Operations Director, Specialty, PCI Pharma Services in a live webinar on Tuesday, September 29, 2020 at 10am EDT (3pm BST/UK) in which they will explore the critical factors that should be considered when choosing the right CDMO for end-to-end high-potent services.

In the webinar, the speakers will discuss accurate potent classification and the importance of OEL assessment. They will also discuss adoption of a risk management approach through SMEPAC testing as a product moves through the various stages of processing from dispensing, through granulation to final dosage.

The presentation will also highlight the best practice of using fully-contained engineering solutions and applying the latest in regulatory guidance, as well as the key considerations for both primary and secondary packaging – this will include specific aspects of packaging highly potent products including, heightened air filtration systems, ISO8 standards, room pressure differentiation and the general principles of containment controls to ensure operator safety.

If you are in the process of assessing your outsourcing options for the development, manufacturing and packaging of highly potent products or simply wish to know more about the processing of such specialist products, this webinar is designed to combine theory with practice, drawing on the experience built up over 35 years of working in this specialist space.

For more information or to register for this event, visit The critical aspects to consider when choosing the right CDMO for your HPAPI Development, Manufacturing & Packaging.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Octapharma Chooses Genedata Selector for NGS-Based Cell Line Development


News Image

Using Genedata Selector we are now able to quickly detect unfavorable properties of a production cell line and engineer preferred properties by editing its genetic background

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Octapharma, one of the world’s leading manufacturers of therapeutic human proteins, has chosen Genedata Selector® as its central computational platform to streamline genomics-based cell line development and cell culture optimization workflows. Genedata Selector enables the efficient analysis of next-generation sequencing (NGS) data in the context of host cell line engineering and clone selection. In addition to a software license agreement, Genedata has entered into a long-term collaboration to provide bioinformatics consulting services to strengthen Octapharma’s innovation projects.

“As part of our innovation strategy, we have started to implement NGS-based workflows in combination with other state-of-the-art technologies, such as targeted locus amplification (TLA) and gene editing in bioprocess development and production,” said Tobias Stuwe, Ph.D., Head of Recombinant R&D at Octapharma. “The need to streamline and automate these highly complex and data-intensive experimental processes was the main reason behind our selection of Genedata Selector. The platform helps us shorten development cycles and increase efficiency.”

“Genedata Selector enables us to integrate a wide variety of complex data generated by novel experimental workflows so we can gain a holistic molecular understanding of production cells with the goal of developing high performing bioproduction processes,” commented Ruth Wagner, Ph.D., Group Manager of Cell Line Engineering at Octapharma. “For example, using Genedata Selector we are now able to quickly detect unfavorable properties of a production cell line and engineer preferred properties by editing its genetic background.”

Genedata Selector provides the foundation for rational design of production cell lines, by delivering comprehensive gene annotation, predicting optimal CRISPR gene editing sites, and calculating all variations in genes of interest within proprietary host cell lines based on RNAseq data. The software platform also supports the automation of clone selection workflows, for example by including efficient data analysis workflows to check integration sites and detect mutations for the analysis of TLA-based experiments. On a more general level, Genedata Selector has been specifically designed to process and interpret huge amounts of complex NGS data in the context of rational cell line development with additional applications such as adventitious agent detection.

“We are excited to collaborate with Octapharma in supporting their innovative cell line development projects,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Over the last few years Genedata has successfully established Genedata Selector as the leading digitalization platform for NGS-based workflows in biopharma R&D with a focus on maximizing our clients’ return on investment in NGS and other omics technologies.”

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Hematology, Immunotherapy, and Critical Care.

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum. In addition, Octapharma operates more than 140 plasma donation centres across Europe and the US. For further information, please visit http://www.octapharma.com.

About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.

http://www.genedata.com

LinkedIn | Twitter | YouTube

Contact

Miles Fisher-Pollard

Genedata

Public Relations

Phone: +41 61 511 85 61

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



‘A Friend or a Foe’, Upcoming Webinar Hosted by Xtalks


Xtalks Logo

Xtalks Life Science Webinars

Importantly, they will recommend key considerations for manufacturers to aid the design of their Early Access Program Strategy and associated implementation plans for Europe to optimise success with future launches.

In the EU, Early Access Programs enable patients to access therapies pre-commercialisation for diseases with high unmet need. Known as ‘Expanded Access Programs’ in the US, these initiatives allow for orphan drugs to be made available to patients with rare diseases before they’ve been formally approved by regulators. While these programs can offer numerous benefits to patients, physicians and manufacturers, decisions made during their set-up can have downstream implications for access and commercialisation potential after marketing authorisation. For example, decisions made around the patient eligibility criteria to access an in-development drug via an Early Access Program sets stakeholder expectations around the unmet need within the disease. This in turn could influence payer decisions around the patient population that they are willing to reimburse when the product finally launches commercially.

In this webinar, featured speakers will bring multi-disciplinary perspectives to the benefits and pitfalls of Early Access Programs in Europe. Through a mix of case examples and direct experiences, they will highlight insights into decisions made during program design, set-up, and ongoing implementation. Importantly, they will recommend key considerations for manufacturers to aid the design of their Early Access Program Strategy and associated implementation plans for Europe to optimise success with future launches.

Join Sophie Schmitz, Managing Partner, Partners4Access, Akshay Kumar, Partner, Partner4Access and Luke Robinson, Head of EU Marketing and UK & Nordics GM, BioCryst Pharmaceuticals in a live webinar on Wednesday, September 30, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Early Access Programs in Europe: ‘A Friend or a Foe’.

ABOUT PARTNERS4ACCESS

Partners4Access are experts in orphan drug, cell and gene therapy access, partnering with the biotechnology industry to support launches worldwide. Our services focus on five key areas: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence.

As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access. Through various media initiatives, P4A are able to inform and shape the conversation around orphan drugs.

The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.

For more information, please visit P4A’s website: http://www.partners4access.com or email at contact@partners4access.com.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Surprise Guest Speaker, Dr. Judy Mikovits, Hits the Big Stage at MLX Fearless


MaxLiving is excited to be hosting the largest chiropractic seminar since the quarantine began. With this seminar comes a guest speaker, Dr. Judy Mikovits, known as one of the most intelligent and principled medical doctors in the world.

Dr. Judy Mikovits is a brilliant researcher shaking up the culture of modern science with her groundbreaking discoveries. From her doctoral thesis, which changed the treatment of HIV-AIDS, saving the lives of millions (including basketball legend Magic Johnson) to her spectacular discovery of a new family of human retroviruses. Her latest research points to a new golden age of health, an idea that is nothing short of revolutionary in these times. In all of her work, Dr. Mikovits has always been on the leading edge of science.

Dr. Judy has always sought to identify truth through evidence-based science. With the current chaos and fear taking control of modern society, she brings an analytical approach to explain the raw truths of health and healing. Hear Dr. Judy’s story and her perspective on the “health-preserving” protocols currently implemented in the US.

Join us at MLX Fearless Virtual to engage in the principle of chiropractic and overall health. This is an opportunity to learn how to become the authority figure destined to restore faith back into your community.

To register for this virtual event, go to https://go.maxliving.com/chiropractic-webinar/

If you are interested in joining the MaxLiving network or in MaxLiving wholesale product opportunities, contact Emily Pugh-Oliver, MaxLiving Doctor Sales Associate, at emily.oliver@maxliving.com.

For press information and media resources, please contact Ray Leake, MaxLiving, at (321) 939-3060, or ray.leake@maxliving.com.

_____________________________________

MaxLiving is a natural healthcare organization founded on five core principles of wellness. The 5 Essentials™ is a natural and effective way to maximize your health by integrating core chiropractic, mindset, nutrition, exercise and oxygen, and minimizing toxin exposure. Our vision of chiropractic and holistic healthcare is recognized through a group of chiropractor partners and practices. MaxLiving exists to transform lives by providing educational seminars, coaching programs, franchise opportunities, and nutritional products and services. We want to educate about the power of chiropractic care and empower people to live a healthy, balanced lifestyle.

Share article on social media or email:

SureClinical Supports Asklepion Phase 2 Trial for COVID-19 Patients


“Using SureClinical, we are confident to be able to accelerate our study startup and improve trial management for our critical study to find effective treatments for COVID-19 patients”

SureClinical, the premier provider of FDA and EU compliance validated eClinical cloud applications today announced its complimentary support for Asklepion Pharmaceuticals Phase 2 COVID-19 trial on the SureClinical Platform.

The goal of Asklepion’s study is to prevent or reduce the severity of Covid 19 (SARS-CoV-2) associated ARDS (Acute, Respiratory Distress Syndrome), reduce the dependency on invasive mechanical ventilation, and duration of time the person is in hospital.

Complimentary COVID-19 Trial Support

In April of this year, SureClinical announced a complimentary COVID-19 eClinical application program to support medical research centers, CRO’s and Sponsors who are developing COVID-19 vaccines and treatments. With six active global COVID-19 treatment studies underway on SureClinical’s Cloud and several more in the planning stages, SureClinical is pleased to support Asklepion Pharmaceuticals important Phase 2 trial with access to its eClinical Cloud Suite to help seek the fastest path to effective treatment for COVID-19.

Faster Study Startup

“We are very grateful to SureClinical for their support of our critical work in this crucial trial. Using SureClinical, we are confident to be able to accelerate our study startup and improve trial management for our critical study to find effective treatments for COVID-19 patients”, stated Gurdyal Kalsi, MD, Asklepion Chief Medical Officer. “In this collaboration, the essence of serving the current health crisis is very apparent.”

ETMF and Platform Support for COVID-19 Trials

“We at SureClinical are proud that our eClinical applications and platform are being used to speed the development and delivery of multiple global COVID-19 treatment and vaccine clinical trials. Our platform provides a digital transformation path for our customers, providing better clinical trial operational intelligence – including historic, current and predictive analysis. Customer supporting data shows that our solutions have accelerated clinical study startup by over 50% in many cases, reducing study startup times from 6-9 months to 3 months or less. When applied to COVID-19 clinical studies, these time savings can be significant in saving lives globally. We have extended our help to others as we all work together to rapidly find, validate and release treatments to combat this pandemic,” states Laurie Pattison, VP of Marketing and Customer Experience at SureClinical.

This trial is just the beginning of the relationship with SureClinical. “The system attributes are easily scalable and our relationship is on a growth trajectory. We believe efficient trial setups can be accomplished more readily with the user-friendly SureClinical technology. It is a top end platform as per the evaluation performed by the Asklepion team” states Dr. Kalsi.

Never before has speed been so important in seeking global therapies and treatments for COVID-19. With a proven track record of reducing study startup time by over 70% from manual, paper or spreadsheet based systems, SureClinical’s eClinical Applications and Enterprise Collaboration Platform helps studies streamline their essential document collection and study startup processes as well as support remote clinical monitoring. SureClinical’s application suite includes FDA 21 CFR Part 11 and EU Annex 11, HIPAA compliance validated solutions for Clinical Trial Management (CTMS), Electronic Trial Master File (eTMF) management, Electronic Investigator Site File (eISF) management, Quality Management (QMS), SureNetwork and SureEsign digital signing.

Making an Impact

SureClinical has been supporting clinical research organizations, medical research centers and BioPharma sponsors since 2014 to streamline clinical trial processes. “Our overall goal has never wavered: to speed the development and delivery of life-saving drugs and therapies to patients through our applications,” states Zack Schmidt, CEO of Sure Clinical. “The market has been good to us. This is the way we can give back when it matters most.”

If you are embarking on a new COVID-19 study and would like to leverage the SureClinical platform, please contact SureClinical to see if you are a candidate for a free trial.

Share article on social media or email: